Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Plain English
back to Plain English Search News Story
Flawed Gene May Lead to Cognitive Problems in Schizophrenia

July 26, 2013. New details about how a defective gene, the nicotinic α7 receptor, may lead to cognitive impairments in schizophrenia have emerged in a study published July 16, 2013, in the Proceedings of the National Academy of Sciences. Led by Min Wang at Yale University in New Haven, Connecticut, researchers examined how the nicotinic α7 receptor interacts with the neurons in the brain that are responsible for a certain kind of memory. To do this, they measured monkeys’ memory and the activity of their neurons after giving different drugs to turn the receptors on and off. They found that turning off the receptors made the neurons less active, while turning them on enhanced the neurons’ activity and improved the monkeys’ memory.

Previous studies have found that having a faulty copy of the nicotinic α7 receptor gene, which is thought to disable some of the brain’s receptors, elevates one’s risk of schizophrenia. The researchers’ findings that the receptors are important for memory suggest a possible reason why cognitive problems are also present in the illness. In addition, the study suggests how drugs that bolster nicotinic α7 receptors, currently in clinical trials, may improve cognition in schizophrenia. (For more details, see the related news story.)—Allison A. Curley.

 
SRF News
SRF Comments
Text Size
Reset Text Size
Email this pageEmail this page

Share/Bookmark
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright